Hanmi CEO On Success And Failure Of License Deals
No Need To Lose Hope When Assets Return
The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.
